|
T3 Technion Technology Transfer (corporately styled T3 ~ Technion Technology Transfer) is the technology transfer unit of the Technion in Israel. The unit operates under the auspices of the Technion Research & Development Foundation. ==Overview== T3 is staffed by an 11-member team whose focus is to commercialize new ideas in science and technology from Technion in Israel, by finding investors and entrepreneurs to develop commercial applications. This includes licensing intellectual property and the establishment of start-up companies. The team has been described as "the private sector's gateway to Technion innovation".〔Washington Israel Business Council - http://www.wa-israel.biz/content.asp?contentid=31〕 As of 2011, 424 patents were granted to Technion innovations, with 845 patents pending. T3's partners include incubators, entrepreneurs, private investors, venture capitalists and angel groups. It also conducts strategic partnerships with multinational companies such as Microsoft, IBM, Intel, Philips, Johnson & Johnson, Coca Cola, and others. The name T3 was taken to represent the three 'Ts' in Technion Technology Transfer, and to indicate that scientific breakthrough is taken to another dimension (cubed) when developed and applied as solutions in the real world.〔Taking Technology transfer to another dimension http://www.focus.technion.ac.il/Nov08/technologyTransferStory1.htm〕 Since 2005, the unit has been managed by Benjamin Soffer, a lawyer who has served on the board of directors of companies including Genegraft, SLP Ltd, Regentis Biomaterials, EORD, Guide-X and Slender Medical. Soffer was special advisor to Israel's Chief Scientist at the Israeli Ministry of Industry and Trade.〔http://silicomventures.com/israel-08/speakers.htm〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「T3 Technion Technology Transfer」の詳細全文を読む スポンサード リンク
|